Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M. Danilova L, et al. Among authors: yarchoan m. Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1. Cancer Immunol Res. 2019. PMID: 31043417 Free PMC article.
Targeting neoantigens to augment antitumour immunity.
Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Nat Rev Cancer. 2017. PMID: 28233802 Free PMC article. Review.
Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Johnson BA 3rd, et al. Among authors: yarchoan m. Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Clin Cancer Res. 2017. PMID: 28373364 Free PMC article. Review.
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS. Shroff RT, et al. Among authors: yarchoan m. Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25. Br J Cancer. 2017. PMID: 28441383 Free PMC article.
Targeting neoantigens to augment antitumour immunity.
Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. Nat Rev Cancer. 2017. PMID: 28835723 No abstract available.
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA. Yarchoan M, et al. Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19. Clin Cancer Res. 2017. PMID: 28928158 Free PMC article.
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS. Shroff RT, et al. Among authors: yarchoan m. Br J Cancer. 2018 Jan;118(2):e2. doi: 10.1038/bjc.2017.418. Epub 2018 Jan 9. Br J Cancer. 2018. PMID: 29315294 Free PMC article. No abstract available.
119 results